Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans

Medical Hypotheses

Volumn 48, Issue 3, 1997, Pages 245-251

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; HEPARIN; PROTEOHEPARAN SULFATE;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0030894836     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90328-5     Document Type: Article

References (94)

1. Vane J R, Ånggård E E, Botting R M. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
2. Rubanyi G M. Endothelium-derived vasoactive factors in health and disease. In: Rubanyi G M, ed. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors, Mount Kisco, NY: Futura Publishing Company, 1991: xi-xix.
3. Haynes W G, Webb D J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-854.
4. Castellot J J Jr, Addonizio M L, Rosenberg R, Karnovsky M J. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol 1981; 90: 372-379.
5. Castellot J J Jr, Favreau L V, Karnovsky M J, Rosenberg R D. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. J Biol Chem 1982; 257: 11256-11260.
6. Colburn P, Buonassisi V. Anti-clotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochem Biophys Res Comm 1982; 104: 220-227.
7. Oohira A, Wight T N, Bornstein P. Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J Biol Chem 1983; 258: 2014-2021.
8. Marcum J A, Rosenberg R D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-1737.
9. Kinsella M G, Wight T N. Structural characterization of heparan sulfate proteoglycan subclasses isolated from bovine aortic endothelial cell cultures. Biochemistry 1988; 27: 2136-2144.
10. Fritze L M S, Reilly C F, Rosenberg R D. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 1985; 100: 1041-1049.
11. Rosenberg R D. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis. Fed Proc 1985; 44: 404-409.
12. Ross R, Glomset J A. Atherosclerosis and the arterial smooth muscle cell. Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-1339.
13. Clowes A W, Karnovsky M J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-626.
14. Guyton J R, Rosenberg R D, Clowes A W, Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980; 46: 625-634.
15. Edelman E R, Adams D H, Karnovsky M J. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci 1990; 87: 3773-3777.
16. Clowes A W, Clowes M M, Vergel S C et al. Heparin and cilazapril together inhibit injury-induced intimal hyperplasia. Hypertension 1991; 18(Suppl II): 65-69.
17. Hoover R L, Rosenberg R, Haering W, Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980; 47: 578-583.
18. Chamley-Campbell J H, Campbell G R. What controls smooth muscle phenotype? Atherosclerosis 1981; 40: 347-357.
19. Majack R A, Clowes A W. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118: 253-256.
20. Majack R A, Bornstein P. Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells. J Cell Biol 1984; 99: 1688-1695.
21. Castellot J J Jr, Beeler D L, Rosenberg R D, Karnovsky M J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984; 120: 315-320.
22. Castellot J J Jr, Cochran D L, Karnovsky M J. Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 1985; 124: 21-28.
23. Castellot J J Jr, Choay J, Lormeau J-C et al. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol 1986; 102: 1979-1984.
24. Reilly C F, Fritze L M S, Rosenberg R D. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol 1986; 11-19.
25. Clowes A W, Clowes M M, Kocher O et al. Arterial smooth muscle cells in vivo: relationship between actin isoform expression and mitogenesis and their modulation by heparin. J Cell Biol 1988; 107: 1939-1945.
26. Paul R, Herbert J M, Maffrand J P et al. Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds. Thromb Res 1987; 46: 793-801.
27. Tan E M L, Levine E, Sorger T et al. Heparin and endothelial cell growth factor modulate collagen and proteoglycan production in human smooth muscle cells. Biochem Biophys Res Comm 1989; 163: 84-92.
28. Castellot J J Jr, Wong K, Herman B et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985; 124: 13-20.
29. Pukac L A, Ottlinger M E. Karnovsky M J. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem 1992; 267: 3707-3711.
30. Au Y P T, Kenagy R D, Clowes M M, Clowes A W. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis 1993; 23(Suppl 1): 177-182.
31. Au Y P T, Montgomery K F, Clowes A W. Heparin inhibits collagenase gene expression mediated by phorbol esterresponsive element in primate arterial smooth muscle cells. Circ Res 1992; 70: 1062-1069.
32. Kenagy R D, Nikkari S T, Welgus H G, Clowes A W. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994; 93: 1987-1993.
33. Herbert J-M, Maffrand J-P. Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity. Biochim Biophys Acta 1991; 1091: 432-441.
34. Fager G, Camejo G, Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin. In Vitro Cell Div Biol 1992; 28A: 168-175.
35. Herbert J M, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. Effect of heparin. FEBS Lett 1992; 301: 155-158.
36. Nugent M A, Karnovsky M J, Edelman E R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 1993; 73: 1051-1060.
37. Grainger D J, Witchell C M, Watson J V et al. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor β-like activity from serum. Cardiovas Res 1993; 27: 2238-2247.
38. Majack R A, Cook S C, Bornstein P. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol 1985; 101: 1059-1070.
39. Snow A D, Bolender R P, Wight T N, Clowes A W. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313-330.
40. r 60 000 collagen. J Cell Biol 1985; 100: 613-619.
41. Stern D, Nawroth P, Marcum J et al. Interaction of anti-thrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 1985; 75: 272-279.
42. Nader H B, Buonassisi V, Colburn P, Dietrich C P. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 1989; 140: 305-310.
43. Morrison P, Lowe-Krentz L J. Heparin induces changes in the synthesis of porcine aortic endothelial cell heparan sulfate proteoglycans. Exp Cell Res 1989; 184: 304-315.
44. Kaji T, Sakuragawa N. Heparin stimulates the release of glycosaminoglycans from cultured human endothelial cells. Thromb Res 1990; 57: 163-168.
45. Herbert J M, Nuti D, Paul R, Maffrand J P. In vitro and ex vivo regulation of vascular smooth muscle cell growth and phenotypic modulation by sulphated polysaccharides. Artery 1988; 16: 1-14.
46. Vairel E G, Bouty-Boye H, Toulemonde F et al. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224.
47. Imai T, Hirate Y, Marumo F. Heparin inhibits endomelin-1 and protooncogene c-fos gene expression in cultured bovine endothelial cells. J Cardiovas Pharm 1993; 22(Suppl 8): 49-52.
48. Yokokawa K, Kohno M, Tahara H et al. Effect of heparin on endothelin-1 production by cultured human endothelial cells. J Cardiovas Pharm 1993; 22(Suppl 8): 46-48.
49. Wilson S K, Solez K, Boitnott J K, Heptinstall R H. The effects of heparin treatment of hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. Am J Pathol 1981; 102: 62-71.
50. Susic D, Mandal A K, Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension 1982; 4: 681-685.
51. Vasdev S, Prabhakaran V, Sampson C A. Heparin lowers blood pressure and vascular calcium uptake in hypertensive rats. Scand J Clin Lab Invest 1991; 51: 321-327.
52. Engelberg H, Kuhn R, Steinman M. A controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis. Circulation 1956; 13: 489-498.
53. Hughes M L Jr, Mortensen F, Shourie L. Comparison of continuous long-term heparin and oral anticoagulant therapy in patients with severe angina pectoris. Am Heart J 1963; 65: 615-627.
54. Böttiger L E, Carlson L A, Engstedt L, Orö L. Long-term heparin treatment in ischaemic heart disease. Acta Med Scand 1967; 182: 245-257.
55. Gertler M M, Leetma H E, Koutrouby R J, Johnson E D. Long-term use of minidose heparin in post-myocardial infarction. In: Bradshaw R A, Wessler S, eds. Heparin. Structure, Function, and Clinical Implications. New York: Plenum Press, 1975: 341-350.
56. Lovell R R H, Denborough M A, Nestel P J, Gogle A J. Phenprocoumon and heparin after acute myocardial infarction. Arch Intern Med 1964; 113: 267-274.
57. Schettler G. Risikofaktoren beim Herzinfarkt: Vorläufige Ergebnisse einer sekundären Präventiv studie mit Heparin. Deutsche Med Wochensch 1972; 97: 533-538.
58. Engelberg H. Heparin and atherosclerosis. A review of old and recent findings. Am Heart J 1980; 99: 359-372.
59. Engelberg H. Update on the relationship of heparin to atherosclerosis and its thrombotic complications. Sem Thromb Hemost 1988; 14(Suppl): 88-105.
60. Grossman B J, Cifonelli J A, Ozoa A K. Inhibition of atherosclerosis in cholesterol-fed rabbits by a heparitin sulfate. Atherosclerosis 1971; 13: 103-109.
61. Bianchini P. Therapeutic potential of non-heparin glycosaminoglycans of natural origin. Sem Thromb Hemost 1989; 15: 365-369.
62. Engelberg H. Heparin, non-heparin glycosaminoglycans, and heparinoids: an overview of their application in atherosclerosis. Sem Thromb Hemost 1991; 17(Suppl 1): 5-8.
63. Day C E, Powell J R, Levy R S. Sulfated polysaccharide inhibition of aortic uptake of low density lipoproteins. Artery 1974; 1: 127-137.
64. Morrison L M, Varma R. Glycosaminoglycans and coronary heart disease. In: Varma R S, Varma R, eds. Glycosaminoglycans and Proteoglycans in Physiological and Pathological Processes of Body Systems. Basel: Karger, 1982: 214-230.
65. Morrison L M, Schjeide O A. Coronary Heart Disease and the Mucopolysaccharides. Springfield, IL: Charles C. Thomas, 1974.
66. Francis S E, Holt C M, Taylor T et al. Heparin and neointimal thickening in an organ culture of human saphenous vein. Atherosclerosis 1992; 93: 155-156.
67. Cambria R P, Ivarsson B L, Fallon J T, Abbot W M. Heparin fails to suppress intimal proliferation in experimental vein grafts. Surgery 1992; 111: 424-429.
68. Chan P, Betteridge L, Schachter M et al. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet 1993; 341: 341-342.
69. Dzau V J, Gibbons G H, Pratt R E. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18(Suppl II): 100-105.
70. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
71. McCarty M F. The neglect of glucosamine as a treatment for osteoarthritis - a personal perspective. Med Hypotheses 1994; 42: 323-327.
72. Drovanti A, Bignamini A A, Rovati A L. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther 1980; 3: 260-272.
73. Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-109.
74. Pujalte J M, Llavore E P, Ylescupidez F R. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 110-114.
75. D'Ambrosio E, Casa B, Bompani R et al. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2: 504-508.
76. Vaz A L. Double-blind clnical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982; 8: 145-149.
77. Vajaradul Y. Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther 1981; 3: 336-343.
78. Tapadinhas J M, Rivera I C, Bignamini A A. Oral glucosamine sulphate in the management of arthrosis: report on a multicentre open investigation in Portugal. Pharmatherapeutica 1982; 3: 157-168.
79. Vidal y Plana R R, Karzel K. Glukosamin. Seine Bedeutung für den Knorpelstoffwechsel der Gelenke. 2. Gelenkknorpel-Untersuchungen. Fortschr Med 1980; 98: 801-806.
80. Vidal y Plana R R, Bizzarri D, Rovati A L. Articular cartilage pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharm Res Comm 1978; 10: 557-569.
81. Karzel K, Domenjoz R. Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycane metabolism of fibroblast cultures. Pharmacology 1971; 5: 337-345.
82. Kim J J, Conrad H E. Effect of D-glucosamine concentration on the kinetics of mucopolysaccharide biosynthesis in cultured chick embryo vertebral cartilage. J Biol Chem 1974; 249: 3091-3097.
83. McCarty M F. Glucosamine for wound healing. Med Hypotheses 1996; 47: 273-275.
84. Tobian L. High-potassium diets markedly protect against stroke deaths and kidney disease in hypertensive rats, an echo from prehistoric days. J Hypertens 1986; 4(Suppl 4): 67-76.
85. Fox P L, DiCorleto P E. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 1988; 241: 453-456.
86. Shimokawa H, Vanhoutte P M. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 1988; 78: 1421-1430.
87. Boulanger C, Schini V B, Hendrickson H, Vanhoutte P M. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 1990; 99: 176-180.
88. 2 synthesis in the rat. Prostaglandins 1987; 33: 17-24.
89. Karpen C W, Merola A J, Trewyn R W et al. Modulation of platelet thromboxane A2 and arterial prostacyclin by dietary vitamin E. Prostaglandins 1981; 22: 651-661.
90. Gilbert V A, Zebrowski E J, Chan A C. Differential effects of megavitamin E on prostacyclin and thromboxane synthesis in streptozotocin-induced diabetic rats. Hormone Metab Res 1983; 15: 320-325.
91. Bennett M R, Evan G I, Schwartz S M. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995; 95: 2266-2274.
92. Ornish D, Brown S E, Scherwitz L W et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-133.
93. Armstrong M L, Heistad D D, Megan M B et al. Reversibility of atherosclerosis. In: Frohlich E D, Brest A N, eds. Preventive Aspects of Coronary Heart Disease. Philadelphia, PA: F A Davis Company, 1990: 113-126.
94. McCarty M F. Up-regulation of intracellular signalling pathway may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PPKC syndrome'. Med Hypotheses 1996; in press.